These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23478210)

  • 1. Affordability of programmes to prevent spontaneous preterm birth in Austria: a budget impact analysis.
    Zechmeister-Koss I; Piso B
    Eur J Public Health; 2014 Feb; 24(1):145-50. PubMed ID: 23478210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of a screen-and-treat program for asymptomatic vaginal infections in pregnancy: towards a significant reduction in the costs of prematurity.
    Kiss H; Pichler E; Petricevic L; Husslein P
    Eur J Obstet Gynecol Reprod Biol; 2006 Aug; 127(2):198-203. PubMed ID: 16303228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The costs of mammography screening in New Zealand: evidence from the pilot programmes.
    Menon A; Devlin NJ; Richardson AK
    N Z Med J; 1994 Dec; 107(991):501-3. PubMed ID: 7830979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of risk-based screening for cervical length to prevent preterm birth.
    Einerson BD; Grobman WA; Miller ES
    Am J Obstet Gynecol; 2016 Jul; 215(1):100.e1-7. PubMed ID: 26880732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preterm birth-associated cost of early intervention services: an analysis by gestational age.
    Clements KM; Barfield WD; Ayadi MF; Wilber N
    Pediatrics; 2007 Apr; 119(4):e866-74. PubMed ID: 17339387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of smoking cessation programmes and a smoking ban in public places: comparing gain in life expectancy and cost effectiveness.
    Højgaard B; Olsen KR; Pisinger C; Tønnesen H; Gyrd-Hansen D
    Scand J Public Health; 2011 Dec; 39(8):785-96. PubMed ID: 21976052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.
    Prusa AR; Kasper DC; Sawers L; Walter E; Hayde M; Stillwaggon E
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005648. PubMed ID: 28692640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting the cost-effectiveness of universal cervical length screening: importance of progesterone efficacy.
    Jain S; Kilgore M; Edwards RK; Owen J
    Am J Obstet Gynecol; 2016 Jul; 215(1):101.e1-7. PubMed ID: 26821336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can post-acute care programmes for older people reduce overall costs in the health system? A case study using the Australian Transition Care Programme.
    Hall CJ; Peel NM; Comans TA; Gray LC; Scuffham PA
    Health Soc Care Community; 2012 Jan; 20(1):97-102. PubMed ID: 21848852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome.
    Shackley P; McGuire A; Boyd PA; Dennis J; Fitchett M; Kay J; Roche M; Wood P
    J Public Health Med; 1993 Jun; 15(2):175-84. PubMed ID: 7688977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
    Lotan Y; Buendia Jiménez I; Lenoir-Wijnkoop I; Daudon M; Molinier L; Tack I; Nuijten MJ
    BJU Int; 2012 Dec; 110(11 Pt C):E1060-7. PubMed ID: 22686216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.
    Kumar M; Birch S; Maturana A; Gafni A
    Health Policy; 2006 Jul; 77(2):233-43. PubMed ID: 16126300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of California prenatal participation in the Special Supplemental Nutrition Program for Women, Infants and Children (WIC) to prevent preterm birth.
    Nianogo RA; Wang MC; Basurto-Davila R; Nobari TZ; Prelip M; Arah OA; Whaley SE
    Prev Med; 2019 Jul; 124():42-49. PubMed ID: 30998955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention.
    Gorsky RD; Farnham PG; Straus WL; Caldwell B; Holtgrave DR; Simonds RJ; Rogers MF; Guinan ME
    Public Health Rep; 1996; 111(4):335-41. PubMed ID: 8711101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa.
    Boulle A; Kenyon C; Skordis J; Wood R
    S Afr Med J; 2002 Oct; 92(10):811-7. PubMed ID: 12432807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
    Bailit JL; Votruba ME
    Am J Obstet Gynecol; 2007 Mar; 196(3):219.e1-7. PubMed ID: 17346527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.